OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.…
OKYO Pharma to Participate in 2026 Jefferies Global Healthcare Conference in London
OKYO Pharma (NASDAQ: OKYO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 1.070 USD on 20 November 2026, down 61.2% over 52 weeks. Its 52-week range is 1.000 USD to 3.200 USD: the price is 66.6% below the high and 7.0% above the low.
Its market capitalisation is 56.15M USD.
OKYO Pharma reports return on equity of -72.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 20.59M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.